SCHEMBL6030342

SCHEMBL6030342

CCCCCCCCNC(=O)Nc1sc(C(=O)N(CC)Oc2ccccc2)c(C)c1C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.41
EPHX1 P07099 4/20 0.41
HTT P42858 4/20 0.41
NPSR1 Q6W5P4 7/20 0.40
MAPT P10636 6/20 0.40
HPGD P15428 5/20 0.40
APOBEC3G Q9HC16 1/20 0.40
LMNA P02545 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
POLB P06746 3/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
KDM4E B2RXH2 2/20 0.37
TP53 P04637 1/20 0.37
THRB P10828 1/20 0.37
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030364 0.90 EPHX1 (0.45) ALDH1A1EPHX1HTTNPSR1MAPT
SCHEMBL6029976 0.87 ALDH1A1 (0.47) ALDH1A1NPSR1MAPTHPGDAPOBEC3G
SCHEMBL6030814 0.85 POLB (0.43) ALDH1A1EPHX1HTTMAPTMEN1
SCHEMBL6030339 0.84 POLB (0.42) ALDH1A1EPHX1HTTMAPTHPGD
SCHEMBL6030506 0.83 ALDH1A1 (0.51) ALDH1A1HTTNPSR1MAPTHPGD
SCHEMBL6030667 0.82 NPC1 (0.46) ALDH1A1EPHX1HTTMAPTHPGD
SCHEMBL6030651 0.82 NPC1 (0.46) ALDH1A1EPHX1HTTMAPTHPGD
SCHEMBL6031046 0.82 ALDH1A1 (0.42) ALDH1A1EPHX1HTTNPSR1MAPT
SCHEMBL6029710 0.82 ALDH1A1 (0.43) ALDH1A1EPHX1HTTNPSR1MAPT
SCHEMBL6030054 0.82 ALDH1A1 (0.43) ALDH1A1EPHX1HTTNPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL ALDH1A1 1832/4885EPHX1 938/4885HTT 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.